Status:
COMPLETED
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
Eligibility Criteria
Inclusion
- Measurable disease tumor available for biopsies
- Life expectancy of at least 3 months
Exclusion
- Known or documented brain metastases prior to Cetuximab therapy
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00207116
Start Date
September 1 2005
End Date
March 1 2006
Last Update
October 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Newark, Delaware, United States